¿¬¼ö°­ÁÂ
´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06
´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ : 2022-11-06
±³À°ÀÏÀÚ : 2022-11-06
±³À°Àå¼Ò : ÄÚ¿¢½º ³²ÂÊ4Ãþ ÄÁÆÛ·±½º·ë  
±³À°ÁÖÁ¦ : (¿ÀÇÁ¶óÀÎ) ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦28Â÷ Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÁöÀºÁ¤
¿¬¶ôó : 02-512-5915  
À̸ÞÀÏ : gyncancer@gyncancer.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í Àü¹®ÀÇ 5¸¸¿ø, Àü°øÀÇ3¸¸¿ø, ¿¬±¸¿ø/°£È£»ç2¸¸¿ø, ÁÂÀå/¿¬ÀÚ/Åä·ÐÀÚ/¸¸65¼¼ÀÌ»ó ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-06 401È£ 09:00~09:10 ºÎÀÎÁ¾¾çÀÇÇлó, JGO Best Reviewer ½Ã»ó½Ä  () 
±âŸ 11-06 401È£ 09:10~09:15 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ¹ßÇ¥  () 
±âŸ 11-06 401È£ 09:15~09:20 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ»ó ¼ö»óÀÚ ¹ßÇ¥  () 
±³À°½Ã°£ 11-06 401È£ 09:20~09:35 Ovarian cancer  ³²¼ÒÇö(¿ï»êÀÇ´ë) 
Åä·Ð 11-06 401È£ 09:35~09:40 Designated discussion  ÀÌÀºÁö(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 09:40~09:55 Cervical cancer and uterine cancer  ³ëÁØÈ£(¼º±Õ°üÀÇ´ë) 
Åä·Ð 11-06 401È£ 09:55~10:00 Designated discussion  Àü¼·(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:00~10:15 Risk classification of endometrial cancer  ¹Ú¼öÁø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:15~10:30 BRCA and HRD in high-grade ovarian cancer  ³²ÀºÁö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 10:30~10:45 PD-L1, TMB, MMR status, and beyond for immunotherapy  ÃÖÀ±Áø(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 401È£ 10:45~11:00 Designated discussion  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
È޽Ġ11-06 401È£ 11:00~11:20 Coffee Break  () 
±³À°½Ã°£ 11-06 401È£ 11:20~11:35 Will the importance of complete cytoreduction continue or shrink?  ±èÅÂÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 11:35~11:50 HIPEC or not, that is the question  ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 11-06 401È£ 11:50~12:05 Are you ready for relapse after PARP inhibitors?  ¹ÚÁ¤¿­(¿ï»êÀÇ´ë) 
Åä·Ð 11-06 401È£ 12:05~12:20 Designated discussion  Á¤´ëÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 12:20~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer  ÃÖöÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 12:35~12:50 Long-term results of PARPi as maintenance in front-line  Antonio González Martín(Clínica Universidad de Navarra) 
½Ä»ç 11-06 401È£ 12:50~13:40 Lunch  () 
±³À°½Ã°£ 11-06 401È£ 13:40~13:55 Less radical surgery in early-stage cervical cancer  ¹èÀ縸(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 13:55~14:10 Quality indicators of the radical surgery  °øÅ¿í(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:10~14:25 CCRT: current standard & future perspective  ±è¿ë¹è(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) 
Åä·Ð 11-06 401È£ 14:25~14:40 Designated discussion  ³ëÁÖ¿ø(Â÷ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:40~14:55 Fertility-preservation in gynecologic cancers  ÀÌ»óÈÆ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 14:55~15:10 How to optimize elderly patients for cancer treatments?  ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 15:10~15:25 Management of immunotherapy and targeted therapies-induced toxicities  ÀåűÔ(°è¸íÀÇ´ë) 
Åä·Ð 11-06 401È£ 15:25~15:40 Designated discussion  ¹Ú¼ºÈ£(ÇѸ²ÀÇ´ë) 
È޽Ġ11-06 401È£ 15:40~16:00 Coffee Break  () 
±³À°½Ã°£ 11-06 401È£ 16:00~16:15 Uterine sarcoma  ¼Ò°æ¾Æ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 16:15~16:30 Ovarian clear cell cancer  ¼­µ¿¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-06 401È£ 16:30~16:45 Ovarian low grade serous cancer  È«´ë±â(°æºÏÀÇ´ë) 
Åä·Ð 11-06 401È£ 16:45~17:00 Designated discussion  ±Çº´¼ö(°æÈñÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 13:40~13:55 Assessment of quality of cancer patients  Á¶ÁÖÈñ(¼º±Õ°ü´ë À¶ÇÕÀÇ°úÇпø) 
±³À°½Ã°£ 11-06 403È£ 13:55~14:10 Tailored surgery for cervical cancer  ±¸À¯Áø(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 14:10~14:25 Guidelines and issues for ovarian cancer treatment  ±è»óÀÏ(°¡Å縯ÀÇ´ë) 
Åä·Ð 11-06 403È£ 14:25~14:35 Discussion  () 
±³À°½Ã°£ 11-06 403È£ 14:35~14:50 ERAS & perioperative management  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-06 403È£ 14:50~15:05 Issue of nursing problem during the acute survival period  ±èÁÖÇö(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 11-06 403È£ 15:05~15:20 Clinical trial and research ethics related to gynecologic oncology  ±è¼ö(¿¬¼¼´ë °£È£´ëÇÐ) 
Åä·Ð 11-06 403È£ 15:20~15:30 Discussion  () 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,206 , ´ñ±Û¼ö : 0

[ºÎ»ê] ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ°ñÀýÇÐȸ ´ã´çÀÚ : Á¤À¯Áø ¿¬¶ôó : 031-551

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,011 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,210 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ BPEX 5Ãþ ÄÁÆÛ·±½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,214 , ´ñ±Û¼ö : 0

[´ë±¸] Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­Á : 2024-03-24

±³À°ÀÏÀÚ : 2024-03-24 ±³À°Àå¼Ò : ´ë±¸ ÀÎÅÍºÒ°í ¸¸Ã̵¿ ÄÁº¥¼ÇȦ 2Ãþ ±³À°ÁÖÁ¦ : Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ ½ÃÇà±â

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,251 , ´ñ±Û¼ö : 0